Edition:
India

Exelixis Announces FDA Approval Of Cabometyx Tablets For Previously Untreated Advanced Renal Cell Carcinoma


Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Exelixis Inc ::EXELIXIS ANNOUNCES U.S. FDA APPROVAL OF CABOMETYX® (CABOZANTINIB) TABLETS FOR PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.EXELIXIS INC - APPROVAL OF CABOMETYX TABLETS EXPANDS INDICATION AND COMES WELL IN ADVANCE OF PDUFA DATE OF FEBRUARY 15, 2018. 

Company Quote

16.42
-0.58 -3.41%
18 Oct 2019